Clinical Edge Journal Scan

Patients with PsA, especially women, likely to have abnormal sleep behavior


 

Key clinical point: Many patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) have impaired sleep despite treatment, with female patients having worse sleep quality than male patients.

Major finding: Overall, 46.6% of patients in the entire cohort had abnormal sleep behavior, with sleep quality being worse in women vs men ( P < .001). Depressive symptoms ( P < .001), female sex ( P = .014), and Disease Activity Score in 28 joints ( P = .003) predicted insomnia in PsA.

Study details: The data come from a retrospective medical chart analysis of 330 patients with spondyloarthritis, including 168 patients with PsA and 162 patients with axSpA.

Disclosures: This study was partly funded by an unrestricted grant from Novartis Pharma GmbH, Germany. Several authors, including the lead author, reported receiving speaker honoraria or research or travel grants or serving on advisory boards for several sources, including Novartis.

Source: Frede N et al. Sleep behaviour differs in women and men with psoriatic arthritis and axial spondyloarthritis with impact on quality of life and depressive symptoms. RMD Open. 2023;9:e002912 (May 19). doi: 10.1136/rmdopen-2022-002912

Recommended Reading

MACE, VTE rates compared between TNF and JAK inhibitors for AxSpA and PsA
Psoriatic Arthritis ICYMI
Commentary: Enthesitis, synovitis, spondyloarthritis, and PsA, June 2023
Psoriatic Arthritis ICYMI
EULAR PsA recommendations update emphasizes safety, nonmusculoskeletal manifestations
Psoriatic Arthritis ICYMI
Brepocitinib shows promise in phase 2 trial for psoriatic arthritis
Psoriatic Arthritis ICYMI
Study supports position of methotrexate in treatment algorithm for PsA
Psoriatic Arthritis ICYMI
Etanercept safe and effective in juvenile psoriatic arthritis
Psoriatic Arthritis ICYMI
Axial spondyloarthritis and PsA with axial involvement are distinct entities
Psoriatic Arthritis ICYMI
Apremilast significantly improves dactylitis and enthesitis in PsA
Psoriatic Arthritis ICYMI
No clinically meaningful difference in response to ustekinumab in younger vs older patients with PsA
Psoriatic Arthritis ICYMI
Serum interleukin-36 alpha: A potential biomarker to differentiate PsA from Behçet’s syndrome
Psoriatic Arthritis ICYMI